Display options
Cite
Verma AS, Mallick P, Dwivedi PD, et al. Exogenous supplementation of . J Pharm Bioallied Sci. 2019;11(3):205-215doi: 10.4103/jpbs.JPBS_216_18.
Verma, A. S., Mallick, P., Dwivedi, P. D., & Singh, A. (2019). Exogenous supplementation of . Journal of pharmacy & bioallied sciences, 11(3), 205-215. https://doi.org/10.4103/jpbs.JPBS_216_18
Verma, Ashish S, et al. "Exogenous supplementation of ." Journal of pharmacy & bioallied sciences vol. 11,3 (2019): 205-215. doi: https://doi.org/10.4103/jpbs.JPBS_216_18
Verma AS, Mallick P, Dwivedi PD, Singh A. Exogenous supplementation of . J Pharm Bioallied Sci. 2019 Jul-Sep;11(3):205-215. doi: 10.4103/jpbs.JPBS_216_18. PMID: 31555026; PMCID: PMC6662038.
Copy Download .nbib Format: NLM
Share it on

J Pharm Bioallied Sci. 2019 Jul-Sep;11(3):205-215. doi: 10.4103/jpbs.JPBS_216_18.

Exogenous supplementation of .

Journal of pharmacy & bioallied sciences

Ashish S Verma, Priyadarshini Mallick, Premendra D Dwivedi, Anchal Singh

Affiliations

  1. Jadavpur University, Kolkata, West Bengal, India.
  2. Department of Microbiology, Asutosh College, Bhowanipore, Kolkata, West Bengal, India.
  3. Food, Drug and Chemical Toxicology Group, Academy of Scientific and Innovative Research (AcSIR), Lucknow, Uttar Pradesh, India.
  4. Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.

PMID: 31555026 PMCID: PMC6662038 DOI: 10.4103/jpbs.JPBS_216_18

Abstract

INTRODUCTION: Hepatotoxicity along with enhanced mortality has remained a major concern during the development of antitumor therapy with the use of cell-free ascites fluid adsorbed (ad-AF) over Protein-A-containing

MATERIALS AND METHODS: Therefore, in this study,

RESULTS: Exogenous supplementation of NAC along with ad-AF treatment to ascites tumor bearers has shown a significant protection against hepatotoxicity and mortality caused by ad-AF. NAC substitution along with ad-AF has significantly enhanced the mean survival time (MST), without altering the antitumor effect of ad-AF as evident from tumor cell counts and viability.

DISCUSSION: NAC supplementation has been successful to recover hepatic -SH contents along with the significant recovery of phase I and phase II biotransformation enzymes. Marker enzymes for liver injury have also given clear-cut indications for the recovery of tumor bearers from hepatotoxicity induced by ad-AF.

CONCLUSION: This study has shown that exogenous supplementation of NAC protects the host from the enhanced mortality and hepatotoxicity induced by ad-AF. These observations offer a hope to develop ad-AF as one of the probable treatment strategies for ascites tumors at least at experimental levels.

Keywords: Adsorbed ascites fluid; Ehrlich’s ascites tumor; N-acetylcysteine; Staphylococcus aureus Cowan I; antitumor; hepatotoxicity; protein A

Conflict of interest statement

There are no conflicts of interest.

References

  1. Immunopharmacol Immunotoxicol. 1999 Feb;21(1):89-108 - PubMed
  2. Toxicol Lett. 1999 Jun 1;106(2-3):119-27 - PubMed
  3. Eur J Clin Invest. 2000 Oct;30(10):915-29 - PubMed
  4. Arzneimittelforschung. 1979;29(4):659-61 - PubMed
  5. Toxicol Appl Pharmacol. 1975 Oct;34(1):128-42 - PubMed
  6. J Biol Chem. 1951 Nov;193(1):265-75 - PubMed
  7. Ann Emerg Med. 2005 Apr;45(4):409-13 - PubMed
  8. Eur J Pharmacol. 2007 Dec 1;575(1-3):142-8 - PubMed
  9. Toxins (Basel). 2010 Aug;2(8):2177-97 - PubMed
  10. Biochem Pharmacol. 1979 Dec 15;28(24):3499-502 - PubMed
  11. West J Emerg Med. 2013 May;14(3):218-26 - PubMed
  12. J Cancer Res Clin Oncol. 1989;115(4):340-4 - PubMed
  13. Toxicol Mech Methods. 2014 Sep;24(6):417-27 - PubMed
  14. Toxicol Lett. 1989 Oct;49(1):1-13 - PubMed
  15. Life Sci. 2016 Apr 15;151:359-363 - PubMed
  16. J Clin Apher. 1986;3(2):133-9 - PubMed
  17. Toxicol Appl Pharmacol. 1986 May;83(3):474-85 - PubMed
  18. J Pharm Bioallied Sci. 2019 Jan-Mar;11(1):23-32 - PubMed
  19. Contemp Top Immunobiol. 1985;15:147-211 - PubMed
  20. Biochem Pharmacol. 1987 Dec 1;36(23):4055-8 - PubMed
  21. J Immunopharmacol. 1986;8(1):39-58 - PubMed
  22. J Immunopharmacol. 1986;8(1):59-73 - PubMed
  23. Eur J Cancer Clin Oncol. 1985 Oct;21(10):1115-22 - PubMed
  24. Cancer Chemother Pharmacol. 1985;14(2):135-8 - PubMed
  25. Cancer. 1985 Jul 15;56(2):266-72 - PubMed
  26. J Biol Chem. 1974 Nov 25;249(22):7130-9 - PubMed
  27. Gan. 1973 Feb;64(1):83-92 - PubMed
  28. J Pharmacol Exp Ther. 1973 Oct;187(1):211-7 - PubMed
  29. Pharmacology. 1974;11(3):151-69 - PubMed
  30. J Pharmacol Exp Ther. 1972 Sep;182(3):474-90 - PubMed
  31. Lancet. 1976 Oct 2;2(7988):738-9 - PubMed
  32. Cancer Res. 1981 Aug;41(8):3244-52 - PubMed
  33. Zentralbl Bakteriol Mikrobiol Hyg A. 1984 Dec;258(4):472-9 - PubMed
  34. J Clin Invest. 1983 Apr;71(4):980-91 - PubMed
  35. Clin Exp Immunol. 1980 Nov;42(2):308-14 - PubMed
  36. Cancer Res. 1982 Dec;42(12):4970-4 - PubMed
  37. Cancer Treat Rep. 1982 Dec;66(12):2027-31 - PubMed
  38. Pediatrics. 1978 Nov;62(5 Pt 2 Suppl):880-9 - PubMed
  39. Toxicology. 1981;19(2):113-25 - PubMed
  40. Am J Physiol. 1993 Feb;264(2 Pt 2):F306-14 - PubMed
  41. Cancer. 1993 Mar 1;71(5):1882-92 - PubMed
  42. Am J Hematol. 1997 Jun;55(2):55-8 - PubMed

Publication Types